sifalimumab   Click here for help

GtoPdb Ligand ID: 8257

Synonyms: MDX-1103 | MEDI-545 | MEDI545
Immunopharmacology Ligand
Compound class: Antibody
Comment: Sifalimumab is a monoclonal antibody targeting interferon α1 (IFNA1), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE). Development of sifalimumab was terminated and MedImmune concentrated on their alternative anti-IFNα agent anifrolumab.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Sequence BLAST using the heavy and light chain variable regions of sifalimumab provides 100% matches to sequences patented with application US7741449 [12]. The sequence matches identify sifalimumab as clone 13H5 in the patent.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
9135 sifalimumab
Synonyms Click here for help
MDX-1103 | MEDI-545 | MEDI545
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 322
Other databases
GtoPdb PubChem SID 249565937
Search PubMed clinical trials sifalimumab
Search PubMed titles sifalimumab
Search PubMed titles/abstracts sifalimumab
Wikipedia Sifalimumab